Effectiveness of sodium-glucose co-transporter-2 inhibitors on ischaemic heart disease.
Yun ShenJian ZhouLizheng ShiElizabeth NaumanPeter T KatzmarzykEboni G Price-HaywoodRonald HorswellSan ChuShengping YangAlessandra N BazzanoSomesh NigamGang Hu
Published in: Diabetes, obesity & metabolism (2020)
The real-world data in the present study show the contribution of SGLT2 inhibitors to reducing risk of ischaemic heart disease, and their benefits beyond glucose-lowering.